Wikipedia
Abituzumab
Abituzumab is a humanized monoclonal antibody (mAb) targeted at CD51 (an integrin).
It is intended to inhibit αv integrins expressed on CRPC cells, tumor vessels, and osteoclasts involved in bone metastasis.
It is in phase II clinical trials for metastatic castration-resistant prostate cancer (CRPC) with evidence of lower incidence of bone lesion progression.